findmyKOL

Gautam Borthakur, MD

Enriched profile

Professor, Department of Leukemia, Division of Cancer Medicine (since 2018); Co-Chief, Section of Developmental Therapeutics; Director of Wellness, Department of Leukemia · The University of Texas MD Anderson Cancer Center

ORCID↗NPI↗
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyHematology / OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Gautam Borthakur is Professor, Department of Leukemia, Division of Cancer Medicine (since 2018); Co-Chief, Section of Developmental Therapeutics; Director of Wellness, Department of Leukemia at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,649 publications with 37,749 citations (h-index 94); ClinicalTrials.gov lists 26 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Gautam Borthakur, M.D., is Professor, Department of Leukemia, Division of Cancer Medicine (since 2018) at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 1,649 publications with 37,749 citations (h-index 94), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 26 registered clinical trials, industry payments reported by 10 companies.

  • Most recent indexed publication: 2026 · American journal of hematology
  • Top research focus: Acute Myeloid Leukemia Research
  • 26 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)19 trialsMDS / MPN16 trialsLeukemia, Myeloid, Acute12 trialsPrimary Myelofibrosis1 trialThrombocytopenia1 trialBlast Crisis1 trialCytopenia1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentAcute Lymphoblastic Leukemia research

Drugs & molecules

across trials, industry payments and publications
Venclextageneric · VenetoclaxClinical trials3Industry payments5Publications33Onureggeneric · AzacitidineClinical trials3Industry payments3Publications9CytarabineClinical trials5Industry payments—Publications9
9 more drug records behind the reveal.Reveal →

Works with

trial sponsors and companies reporting payments
M.D. Anderson Cancer CenterClinical trials20Industry payments—AstraZeneca Pharmaceuticals LPClinical trials—Industry payments6Abbvie Inc.Clinical trials—Industry payments5
12 more company records behind the reveal.Reveal →

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,649publications

Distinct works indexed by OpenAlex, matched via ORCID; 140 in PubMed.

37,749citations

Total citations across indexed works.

94h-index

Hirsch index (OpenAlex). i10-index 540.

Clinical & industry

trials, payments and federal funding
26clinical trials

Investigator role on registered studies.

View trials ↓
10companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 26 registered studies on ClinicalTrials.gov. The most recent:

23 more trial records behind the reveal.Reveal →

Industry payments

Updated 27 Aug 2026

10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

11 more payment records behind the reveal.Reveal →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    51.7%
    BCL-2 Inhibitor39.7%
    Venclexta100%
    Part D≥11 patients
    Antimetabolite12.1%
    Hydroxyurea100%
    Part D<11 patients

  • Anti-infectives

    48.3%
    Fluoroquinolone Antibacterial19.8%
    Levofloxacin100%
    Part D≥12 patients
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.1%
    Valacyclovir100%
    Part D≥12 patients
Where care is delivered (Part B)97.4% facility · 2.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

135 more publications behind the reveal.Reveal →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Acute myeloid leukemia: current progress and future directions
    761 citations2021
    doi.org ↗
  2. 02
    Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
    735 citations2013
    doi.org ↗
  3. 03
    Ibrutinib and Venetoclax for First-Line Treatment of CLL
    504 citations2019
    doi.org ↗
  4. 04
    Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
    416 citations2009
    doi.org ↗
  5. 05
    Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
    382 citations2020
    doi.org ↗
1,644 more cited works behind the reveal.Reveal →

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/gautam-borthakur-346a96130

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • LinkedIn

    linkedin.com/in/gautam-borthakur-a17638109

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/profile/Gautam-Borthakur

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
3 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Other

    faculty.mdanderson.org/profiles/gautam_borthakur.html

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Other

    muckrack.com/gautam-borthakur

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →muckrack.com ↗
  • Other

    onclive.com/view/dr-borthakur-on-the-select-mds-1-trial-in-newly-diagnosed-mds

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
3 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Editorial Board Member

    American Journal of Hematology, 2019-2022

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Editorial Board Member

    Leukemia & Lymphoma, 2021-Present

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Editorial Board Member

    Acta Haematologica

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
7 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
1 more award behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Senator

    Faculty Senate; Member, Executive Committee of Faculty Senate, The University of Texas MD Anderson Cancer Center, 2020-Present

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Vice-Chair

    Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2019-Present

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Co-Chief

    Section of Developmental Therapeutics, Department of Leukemia, MD Anderson Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
2 more affiliations behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.